Table 1 Baseline characteristics of Abi and Doc treated patients.

From: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer

Parameters

Abi

Doc

Total number of patients

100

69

Age (range)

70.8 (52.0–90.0)

70.5 (43.8–86.1)

PSA (ng/mL)

66.5 (0.1–6785.0)

73.7 (3.2–6115.4)

ECOG PS (%)

 0

58 (58)

43 (62)

 1

14 (14)

17 (25)

 2

0 (0)

9 (13)

 unknown

28 (28)

0 (0)

Metastases (%)

 bone

87 (87)

64 (93)

 LN (>2 cm)

18 (18)

7 (10)

 soft tissue

10 (10)

24 (35)

Primary local therapy (%)

 prostatectomy

43 (43)

14 (20)

 radiation

18 (18)

9 (13)

Therapy line (%)

 1st line

44 (44)

62 (90)

 2nd line

55 (55)

7 (9)

 3rd line

1 (1)

0 (0)

PSA response (%) >30

74 (74)

42 (60)

 >50

64 (64)

34 (49)

 >90

28 (28)

22 (32)

Number of patients died

69 (69)

55 (80)

OS median, months

19.0

24.1

Back to article page